Researchers at the University of Kansas Cancer Center have received a $4.2 million, five-year grant from NCI to study the effects of bazedoxifene and low-dose conjugated estrogen in women who are at increased risk for developing breast cancer and are experiencing menopausal symptoms.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe